Merck signs exclusive global license with SciBrunch for KRAS G12D drug SPR2015 in USD 2.13 billion deal
PUBT · 1d ago
Share
Listen to the news
- Merck signed an exclusive global license with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D (ON) inhibitor.
- Deal grants worldwide rights to develop, manufacture, commercialize SPR2015.
- SciBrunch to receive USD 400 million upfront.
- Milestone payments could lift total potential deal value to USD 2.13 billion across multiple indications.
- Merck expects a USD 400 million pre-tax charge in Q3 2026, about USD 0.13 per share.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609280645BIZWIRE_USPR_____20260928_BW125137) on September 28, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending